{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:40:17Z","timestamp":1737445217970,"version":"3.33.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-024-00562-y","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:59:45Z","timestamp":1737442785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing\u2013remitting multiple sclerosis: a systematic review"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-1834","authenticated-orcid":false,"given":"Carlo","family":"Lazzaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-511X","authenticated-orcid":false,"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-934X","authenticated-orcid":false,"given":"Mauro","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-7743","authenticated-orcid":false,"given":"Rocco","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1763","authenticated-orcid":false,"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"562_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13561-024-00478-7","volume":"14","author":"NA Gallehzan","year":"2024","unstructured":"Gallehzan NA, Khosravi M, Jamebozorgi K, et al. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing\u2013remitting multiple sclerosis: a systematic review. Health Econ Rev. 2024;14:12. https:\/\/doi.org\/10.1186\/s13561-024-00478-7.","journal-title":"Health Econ Rev"},{"issue":"8","key":"562_CR2","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1007\/s10072-022-06022-x","volume":"43","author":"C Lazzaro","year":"2022","unstructured":"Lazzaro C, Bergamaschi R, Zaffaroni M, Totaro R, Paolicelli D. Cost-utility analysis of teriflunomide in na\u00efve vs. previously treated patients with relapsing\u2013remitting multiple sclerosis in Italy. Neurol Sci. 2022;43(8):4933\u201344. https:\/\/doi.org\/10.1007\/s10072-022-06022-x.","journal-title":"Neurol Sci"},{"issue":"4","key":"562_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13(4):322\u201338. https:\/\/doi.org\/10.1177\/0272989X9301300409.","journal-title":"Med Decis Mak"},{"key":"562_CR4","unstructured":"Drummond MF, Sculpher MJ, Claxton K et al. Methods for the economic evaluation of health care programmes. Fourth Edition. Oxford: Oxford University Press, 2015."},{"issue":"Italian","key":"562_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF03320660","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore G, per Gruppo di lavoro Associazione Italiana di Economia Sanitaria (AIES). Proposta Di Linee Guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics \u2013 Italian Res Articles. 2009;11(Italian):83\u201393. https:\/\/doi.org\/10.1007\/BF033.","journal-title":"PharmacoEconomics \u2013 Italian Res Articles"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-024-00562-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:59:48Z","timestamp":1737442788000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-024-00562-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1186\/s13561-024-00562-y","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This contribution was exempt from ethical review due to it being a Commentary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Authors declare no conflicts of interest\/competing interests with this Commentary. CL has received teaching fees from University of Pavia, research grants, speaker or consultancy fees from argenx BV, AstraZeneca S.p.A, Ipsen S.p.A., Janssen-Cilag SPA, Horizon Therapeutics srl, Roche S.p.A., Roche Diagnostics S.p.A., Sanofi s.r.l., Santen GmbH, Santen Italy S.R.L. RB has served on scientific advisory boards for Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received research support from Almirall, Bayer, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme; received support for travel and congress from Biogen, Roche, Merck-Serono, Sanofi-Genzyme, Teva; received honoraria for speaking engagement from Biogen, Merck-Serono, Novartis, Sanofi-Genzyme. MZ has served on scientific advisory boards and received honoraria for speaking or support for travel and congress attendance from Almirall, Biogen, Merck-Serono, Novartis, Sanofi-Genzyme. RT has received speaker or consultancy fees from Biogen, Merck-Serono, Novartis, Roche, Sanofi and Teva. DP has received honoraria for consultancy and\/or speaking from Biogen Idec, Merck-Serono, Bayer-Schering, Sanofi-Aventis, TEVA, Novartis and Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Authors declare that no section of this Commentary was supported by Artificial Intelligence.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative artificial intelligence in scientific writing"}}],"article-number":"3"}}